Literature DB >> 27679679

Omalizumab: A useful tool for inducing tolerance to bee venom immunotherapy.

L Ricciardi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27679679      PMCID： PMC5806845          DOI： 10.1177/0394632016670920

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN： 0394-6320            Impact factor:   3.219


× No keyword cloud information.
  14 in total

1.  Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology.

Authors:  H Mosbech; U Müller
Journal:  Allergy       Date:  2000-11       Impact factor: 13.146

2.  Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE.

Authors:  Kalliopi Kontou-Fili; Christos I Filis; Christina Voulgari; Panayiotis G Panayiotidis
Journal:  Ann Allergy Asthma Immunol       Date:  2010-06       Impact factor: 6.347

Review 3.  Anaphylaxis to insect stings.

Authors:  David B K Golden
Journal:  Immunol Allergy Clin North Am       Date:  2015-03-06       Impact factor: 3.479

4.  Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.

Authors:  Elizabeth Nicole da Silva; Katrina Louise Randall
Journal:  J Allergy Clin Immunol Pract       Date:  2013-09-08

5.  Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.

Authors:  Marc Massanari; Harold Nelson; Thomas Casale; William Busse; Farid Kianifard; Gregory P Geba; Robert K Zeldin
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

Review 6.  Omalizumab and hypersensitivity reactions.

Authors:  Tara Shankar; Andrej A Petrov
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

7.  Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.

Authors:  C Galera; N Soohun; N Zankar; S Caimmi; C Gallen; P Demoly
Journal:  J Investig Allergol Clin Immunol       Date:  2009       Impact factor: 4.333

8.  Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.

Authors:  M V Kopp; E Hamelmann; S Zielen; W Kamin; K-C Bergmann; C Sieder; S Stenglein; S Seyfried; U Wahn
Journal:  Clin Exp Allergy       Date:  2008-10-30       Impact factor: 5.018

9.  The bee sting that was not: an unusual case of hymenoptera anaphylaxis averted in a patient treated with omalizumab for asthma.

Authors:  Evelyn M Slaughter; Nathan Boyer; Steven Bennett
Journal:  Case Rep Med       Date:  2014-08-12

Review 10.  Venom immunotherapy for preventing allergic reactions to insect stings.

Authors:  Robert J Boyle; Mariam Elremeli; Juliet Hockenhull; Mary Gemma Cherry; Max K Bulsara; Michael Daniels; J N G Oude Elberink
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17
View more
  7 in total

Review 1.  The pathophysiology of anaphylaxis.

Authors:  Laurent L Reber; Joseph D Hernandez; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2017-08       Impact factor: 10.793

2.  Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.

Authors:  Askin Gülsen; Franziska Ruëff; Uta Jappe
Journal:  Allergol Select       Date:  2021-03-11

Review 3.  Novel strategies in immunotherapy for allergic diseases.

Authors:  Mohana Rajakulendran; Elizabeth Huiwen Tham; Jian Yi Soh; H P Van Bever
Journal:  Asia Pac Allergy       Date:  2018-04-09

Review 4.  Allergen-specific immunotherapy of Hymenoptera venom allergy - also a matter of diagnosis.

Authors:  Maximilian Schiener; Anke Graessel; Markus Ollert; Carsten B Schmidt-Weber; Simon Blank
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

Review 5.  Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.

Authors:  Teodorikez Wilfox Jimenez-Rodriguez; Marlene Garcia-Neuer; Leila A Alenazy; Mariana Castells
Journal:  J Asthma Allergy       Date:  2018-06-20

Review 6.  Pathophysiological, Cellular, and Molecular Events of the Vascular System in Anaphylaxis.

Authors:  Emilio Nuñez-Borque; Sergio Fernandez-Bravo; Alma Yuste-Montalvo; Vanesa Esteban
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

Review 7.  Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.

Authors:  Simon Blank; Johannes Grosch; Markus Ollert; Maria Beatrice Bilò
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.